AXA trimmed its holdings in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 2.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 561,121 shares of the biotechnology company’s stock after selling 13,799 shares during the period. AXA owned 1.56% of Five Prime Therapeutics worth $3,383,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in FPRX. Parametric Portfolio Associates LLC lifted its holdings in Five Prime Therapeutics by 227.8% in the second quarter. Parametric Portfolio Associates LLC now owns 44,855 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 31,173 shares during the period. Athanor Capital LP bought a new position in Five Prime Therapeutics during the 2nd quarter worth about $104,000. Alambic Investment Management L.P. bought a new position in Five Prime Therapeutics during the 2nd quarter worth about $69,000. Northern Trust Corp grew its holdings in Five Prime Therapeutics by 2.8% during the 2nd quarter. Northern Trust Corp now owns 443,191 shares of the biotechnology company’s stock worth $2,672,000 after acquiring an additional 12,054 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Five Prime Therapeutics by 86.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,149,200 shares of the biotechnology company’s stock worth $6,930,000 after acquiring an additional 533,100 shares in the last quarter. Institutional investors own 74.22% of the company’s stock.
Several research analysts have issued reports on FPRX shares. Guggenheim cut shares of Five Prime Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, September 30th. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, ValuEngine upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. Five Prime Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $14.40.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.09). The business had revenue of $3.33 million during the quarter, compared to analyst estimates of $5.53 million. Five Prime Therapeutics had a negative return on equity of 62.13% and a negative net margin of 842.84%. As a group, equities research analysts anticipate that Five Prime Therapeutics Inc will post -3.91 EPS for the current fiscal year.
In other Five Prime Therapeutics news, major shareholder Bvf Partners L. P/Il acquired 16,000 shares of the stock in a transaction on Friday, October 4th. The stock was purchased at an average price of $3.74 per share, for a total transaction of $59,840.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Bvf Partners L. P/Il acquired 525,070 shares of the stock in a transaction on Monday, October 7th. The shares were acquired at an average price of $3.75 per share, with a total value of $1,969,012.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 1,142,552 shares of company stock valued at $4,278,395. 7.10% of the stock is owned by insiders.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Article: Gap Up Stocks
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.